ARTICLE | Company News

Novera Therapeutics, J&J deal

October 19, 2015 7:00 AM UTC

Johnson & Johnson’s Janssen Biotech Inc. unit partnered with Novera to develop and commercialize therapies for B cell malignancies. Novera will discover and develop compounds identified through the Ontario Institute for Cancer Research (Toronto, Ontario) drug discovery program with University Health Network (Toronto, Ontario). Janssen will collaborate with Novera on the therapies’ development and will have an option to obtain exclusive, worldwide rights to the therapies. ...